100706-药理学

肿瘤药理

2001-09--2006-06   中国科学院上海药物研究所   博士
1993-09--1998-06   上海医科大学   大学本科

   

2018-10~现在, 中国科学院上海药物研究所, 研究员
2008-09~2018-09,中国科学院上海药物研究所, 副研究员
2006-07~2008-08,中国科学院上海药物研究所, 助理研究员
2001-09~2006-06,中国科学院上海药物研究所, 博士
1998-07~2001-08,上海市长宁区中心医院, 临床药师
1993-09~1998-06,上海医科大学, 大学本科

2011-01-01-今,中国药理学会会员,

   

（ 1 ） 12. 6-(4-(二氟甲氧基)-3-甲氧基苯基)哒嗪-3(2H)-酮在制备抗肿瘤药物中的用途, 2011, 第 5 作者, 专利号: 201110196266.4

（ 2 ） 一种水溶性S,S-型庚铂衍生物, 2011, 第 4 作者, 专利号: CN102079761A

   

（1） X66, a novel N-terminal heat shock protein 90 inhibitor, exerts antitumor effects without induction of heat shock response, oncotarget, 2016, 通讯作者
（2） Y-632 inhibits heat shock protein 90 (Hsp90) function by disrupting the interaction between Hsp90 and Hsp70/Hsp90 organizing protein, and exerts antitumor activity in vitro and in vivo, cancer science, 2016, 第 4 作者
（3） NL-103, a novel dual-targeted inhibitor of histone deacetylases and hedgehog pathway, effectively overcomes vismodegib resistance conferred by Smo mutations, Pharma Res Per, 2014, 第 3 作者
（4） Synthesis, anticancer activity and toxicity of a water-soluble 4S,5S-derivative heptaplatin,cis-{Pt(II)[(4S,5S)-4,5-bis(aminomethyl)-2- isopropyl-1, 3-dioxolane]• (3-hydroxyl-cyclobutane-1,1-dicarboxylate)}, J Inorg Biochem, 2014, 第 3 作者
（5） Phosphodiesterase 3/4 inhibitor zardaverine exhibits potent and selective antitumor activity against hepatocellular carcinoma both in vitro and in vivo independently of phosphodiesterase inhibition, PLoS One, 2013, 第 3 作者
（6） RON confers lapatinib resistance in HER2-positive breast cancer cells, cancer letter, 2013, 第 4 作者
（7） A novel and simple hollow-fiber assay for in vivo evaluation of nonpeptidyl thrombopoietin receptor agonists, Exp Hematol, 2012, 第 1 作者
（8） Antitumor activity of lobaplatin alone or in combination with antitubulin agents in non-small cell lung cancer, Anticancer drugs, 2012, 第 1 作者
（9） YHHU0895, a novel synthetic small-molecule microtubule-destabilizing agent, effectively overcomes P-glycoprotein-mediated tumor multidrug resistance, Cancer Lett, 2012, 第 3 作者
（10） Synthesis and cytotoxicity of diam(m) ineplatinum(II) complexes with 2,2-bis(hydroxymethyl)malonate as the leaving group, Bioorg Med Chem Lett , 2012, 通讯作者
（11） YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo, Cancer Sci, 2011, 第 3 作者
（12） A novel water-soluble heptaplatin analogue with improved antitumor activity and reduced toxicity, Inorg Chem , 2011, 通讯作者
（13） HH-GV-678, a novel selective inhibitor of Bcr-Abl, outperforms imatinib and effectively overrides imatinib resistance, Leukemia, 2010, 第 3 作者
（14） .MFTZ-1, an actinomycetes subspecies derived antitumor macrolide, functions as a novel topoisomerase II poison, Mol Cancer Ther, 2007, 第 1 作者
（15） Silencing of heparanase by siRNA inhibits tumor metastasis and angiogenesis of human breast cancer in vitro and in vivo,  Cancer Biol Ther, 2007, 第 4 作者

   

（ 1 ） 以EGFR、KDR、HER2、VEGFR为靶点的抗肿瘤创新药物药效学研究, 负责人, 其他国际合作项目, 2009-11--2020-11
（ 2 ） 同时靶向癌细胞能量代谢和DNA复制的新型铂类配合物设计、合成和抗肿瘤作用研究, 参与, 国家任务, 2012-01--2015-12
（ 3 ） PI3K抑制剂XC-302的抗肿瘤作用机理研究, 负责人, 国家任务, 2009-01--2011-12
（ 4 ） 新型Hsp90抑制剂X66抗肿瘤作用分子机理研究, 负责人, 国家任务, 2013-01--2016-12

（1）Preclinical study of puquitinib, a novel orally available PI3K inhibitor in phase I clinical trials   chengying xie yongping xu liguang lou   2011-04-02